Fundación Pública Gallega de Medicina Genómica
Centro de investigación
Universidad de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Salamanca (20)
2024
2023
2022
-
Experimental Setup for Irradiation of Cell Cultures at L2A2
Quantum Beam Science, Vol. 6, Núm. 1
-
Novel genes and sex differences in COVID-19 severity
Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806
2021
-
Predictors of cardiovascular events and all-cause of death in patients with transfusion-dependent myelodysplastic syndrome
British Journal of Haematology, Vol. 195, Núm. 4, pp. 536-541
2016
-
Gene–gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients
Drug Metabolism and Pharmacokinetics, Vol. 31, Núm. 5, pp. 349-355
-
High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma
Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262
2015
-
Translational value of animal models of kidney failure
European Journal of Pharmacology, Vol. 759, pp. 205-220
2014
-
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers
Breast Cancer Research and Treatment, Vol. 148, Núm. 2, pp. 415-421
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
2013
-
Evaluation of Rare Variants in the New Fanconi Anemia Gene ERCC4 (FANCQ) as Familial Breast/Ovarian Cancer Susceptibility Alleles
Human Mutation, Vol. 34, Núm. 12, pp. 1615-1618
-
First symposium of ichthyosis experts
Actas Dermo-Sifiliograficas
-
Impact of pharmacogenetics on CNS side effects related to efavirenz
Pharmacogenomics, Vol. 14, Núm. 10, pp. 1167-1178
-
Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations
British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86
2012
-
Shorter telomere length is associated with increased: Ovarian cancer risk in both familial and sporadic cases
Journal of Medical Genetics, Vol. 49, Núm. 5, pp. 341-344
2010
-
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
Breast Cancer Research and Treatment, Vol. 119, Núm. 1, pp. 221-232
2008
-
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain
Clinical Cancer Research, Vol. 14, Núm. 9, pp. 2861-2869
2006
-
Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancer
Clinical Chemistry, Vol. 52, Núm. 8, pp. 1480-1485
2003
-
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects
Human Mutation, Vol. 22, Núm. 4, pp. 301-312